Consensus guidance for prevention and management of nausea and vomiting in patients treated with zolbetuximab + chemotherapy: a RAND/UCLA modified Delphi panel study

Samuel J. Klempner; Roberto Pazo-Cid; Sara Lonardi; Laura C Swanson; Matthew J. Arango; Peter C. Enzinger; Andrew H. Ko; Gina M. Vaccaro; K. Yamaguchi; Anwaar Saeed; K.-W. Lee; Kohei Shitara; David H. Ilson; Jaffer A. Ajani; Rupali Fuldeore; Stéphanie Braun; Michael S. Broder; Manali Shah

doi:10.1016/j.esmogo.2024.100131

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

These consensus-based guidelines can be utilized by clinicians to guide the prevention and management of nausea and vomiting in patients treated with zolbetuximab plus chemotherapy so that patients can continue receiving treatment and achieve benefits.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Klempner et al. (2025) studied this question.

synapsesocial.com/papers/69d88d6ad2f7327e70ae35ca https://doi.org/10.1016/j.esmogo.2024.100131

View Full Paper

Ask AI

Bookmark

Share

Consensus guidance for prevention and management of nausea and vomiting in patients treated with zolbetuximab + chemotherapy: a RAND/UCLA modified Delphi panel study

Ask about this paper

Abstract

Discussion

Cite This Study

Consensus guidance for prevention and management of nausea and vomiting in patients treated with zolbetuximab + chemotherapy: a RAND/UCLA modified Delphi panel study

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading